ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.73
0.23%
US Tech 100
21,212.97
0.07%
S&P 500
6,046.26
1.21%
US Dollar vs CAD
1.44059
0.36%
Bitcoin
96,426.07
-2.90%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Leap Therapeutics Inc (LPTX) Share Price

Leap Therapeutics Inc

Leap Therapeutics Inc (LPTX)

NASDAQ
3.02
0.11
( 3.78% )
Updated: 10:55:55
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.02
Bid
2.99
Ask
3.02
Volume
54,871
2.8888 Day's Range 3.02
1.68 52 Week Range 5.00
Market Cap
115.72M
Previous Close
2.91
Open
2.95
Last Trade
25
@
3.005
Last Trade Time
10:58:31
Financial Volume
US$ 162,327
VWAP
2.9583
Average Volume (3m)
373,312
Shares Outstanding
38,317,897
Dividend Yield
-
PE Ratio
-1.42
Earnings Per Share (EPS)
-2.12
Revenue
-
Net Profit
-81.41M

About Leap Therapeutics Inc

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhib... Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.leaptx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Leap Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LPTX. The last closing price for Leap Therapeutics was US$2.91. Over the last year, Leap Therapeutics shares have traded in a share price range of US$ 1.68 to US$ 5.00.

Leap Therapeutics currently has 38,317,897 shares outstanding. The market capitalization of Leap Therapeutics is US$111.51 million. Leap Therapeutics has a price to earnings ratio (PE ratio) of -1.42.

Ask ADVFN Intelligence (AI)

LPTX Latest News

More News

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference PR Newswire CAMBRIDGE, Mass., Nov. 26, 2024 CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics...

November 26 2024
PR Newswire (US)

Form 8-K - Current report

November 13 2024
Edgar (US Regulatory)

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics Reports Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Nov. 13, 2024 CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a...

November 13 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 13 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

November 06 2024
Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

October 31 2024
Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

October 31 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

October 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

October 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

October 04 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.06772.29312739222.95233.022.751997422.8606869CS
4-0.05-1.628664495113.073.442.74834139913.06548861CS
120.544221.98077389132.47584.792.23733123.17808632CS
261.265.93406593411.824.791.682352942.98000058CS
52-0.3-9.036144578313.3251.682543203.01148269CS
156-26.115-89.634460271229.13534.491.23557004010.67918621CS
260-7.58-71.509433962310.641.71.23592068719.31247199CS

LPTX - Frequently Asked Questions (FAQ)

What is the current Leap Therapeutics share price?
The current share price of Leap Therapeutics is US$ 3.02
How many Leap Therapeutics shares are in issue?
Leap Therapeutics has 38,317,897 shares in issue
What is the market cap of Leap Therapeutics?
The market capitalisation of Leap Therapeutics is USD 111.51M
What is the 1 year trading range for Leap Therapeutics share price?
Leap Therapeutics has traded in the range of US$ 1.68 to US$ 5.00 during the past year
What is the PE ratio of Leap Therapeutics?
The price to earnings ratio of Leap Therapeutics is -1.42
What is the reporting currency for Leap Therapeutics?
Leap Therapeutics reports financial results in USD
What is the latest annual profit for Leap Therapeutics?
The latest annual profit of Leap Therapeutics is USD -81.41M
What is the registered address of Leap Therapeutics?
The registered address for Leap Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Leap Therapeutics website address?
The website address for Leap Therapeutics is www.leaptx.com
Which industry sector does Leap Therapeutics operate in?
Leap Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SKKSKK Holdings Limited
US$ 2.38
(218.18%)
34.69M
MGIHMillennium Group International Holdings Ltd
US$ 4.34
(183.66%)
68.6M
SPRCSciSparc Ltd
US$ 0.4891
(121.11%)
202.67M
AIREreAlpha Tech Corporation
US$ 2.485
(81.39%)
38.65M
ZCARZoomcar Holdings Inc
US$ 2.43
(69.93%)
51.95M
BAOSBaosheng Media Group Holdings Ltd
US$ 4.085
(-42.46%)
1.26M
NEUPNeuphoria Therapeutics Inc
US$ 4.402
(-33.60%)
395.99k
SVRESaverOne 2014 Ltd
US$ 1.0092
(-33.17%)
922.95k
GTIGraphjet Technology
US$ 0.409992
(-32.79%)
13.39M
HOURHour Loop Inc
US$ 3.2701
(-25.68%)
4.7M
SPRCSciSparc Ltd
US$ 0.4891
(121.11%)
202.67M
COEPCoeptis Therapeutics Holdings Inc
US$ 0.2067
(45.56%)
178.3M
XTIAXTI Aerospace Inc
US$ 0.0418
(6.63%)
158.3M
RGTIRigetti Computing Inc
US$ 14.2197
(25.28%)
127.23M
SMXSMX Security Matters Public Company
US$ 0.331
(51.83%)
110.53M

LPTX Discussion

View Posts
ANTADOG ANTADOG 6 days ago
hearin' some good things comin' our way, hmm, u got to pay to play, ANT
👍️0
ANTADOG ANTADOG 2 weeks ago
Added 2,96~~ ANT
👍️0
ANTADOG ANTADOG 2 weeks ago
3,40~~ because they know... ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
accumulated a nice amount around 3 bucks, longterm, ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
3,35~~ ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
3,33~~ ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
Volume intact, ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
hooverin' above 3 bucks, ceo certainly gave them somethin' to think about, to be continued.... ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
3,33~~ ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
3,24~~ ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
3,19~~ ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
mm in trouble lol, ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
3,12~~ ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
3,10 break is close, hmm, ANT
👍️0
ANTADOG ANTADOG 3 weeks ago
added some 2,80's, likin' the chart, ANT
👍️0
glenn1919 glenn1919 4 weeks ago
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
ANTADOG ANTADOG 2 months ago
And some more 3,25's longterm, ANT
👍️0
ANTADOG ANTADOG 2 months ago
added 3,70 ANT
👍️0
ANTADOG ANTADOG 2 months ago
held first support, startin' to like this one more and more, gild support, fyi ANT
👍️0
ANTADOG ANTADOG 2 months ago
added first support, ANT
👍️0
ANTADOG ANTADOG 2 months ago
consistent buyin' often means deeper pockets like what they see or are about to find out, so they add while it's cheap, imo but we'll see soon, ANT
👍️0
ANTADOG ANTADOG 2 months ago
puppy's goin' for a new 52wk high imo ANT
👍️0
ANTADOG ANTADOG 2 months ago
because it's a double digitland stock, xcellent results will propel it imosho ANT
👍️0
joelawyer joelawyer 2 months ago
Any clue what's driving this major upside move the last week?

👍️0
glenn1919 glenn1919 2 months ago
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 months ago
LPTX under $3
👍️0
Monksdream Monksdream 5 months ago
LPTX under $3
👍️0
Monksdream Monksdream 6 months ago
LPTX under $2
👍️0
Monksdream Monksdream 8 months ago
LPTX under $5
👍️0
glenn1919 glenn1919 8 months ago
LPTX...................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 months ago
LPTX 10Q due March 12
👍️0
glenn1919 glenn1919 1 year ago
LPTX.......................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
LPTX................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
LPTX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
LPTX new 52 week low
👍️0
Slicky1315 Slicky1315 2 years ago
Wow..almost a year and no one posted anything!!
👍️0
VivaLasVegas VivaLasVegas 3 years ago
No one in their right mind gives 2 Sheets what some joke analyst gives for any price target

They are Shills
👍️0
stockguard stockguard 3 years ago
LPTX Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update Jan. 23
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Leap Therapeutics (LPTX) to $6 from $5 and keeps an Overweight rating on the shares. Following the ASCO GI update for DKN-01, Leap hosted a conference call on Friday to walk through the data and lay out potential next steps, the analyst notes. When considering potential treatment effect, Catanzaro thinks the signal in DKK1-high patients looks even more compelling. Leap believes it could initiate a small randomized Phase II as part of the current IND that could generate data in 2023, while simultaneously engaging regulatory agencies on registrational strategies. Most notably, BeiGene's (BGNE) opt-in decision for Asian rights will almost certainly be a 2022 event, and the analyst continues to believe the ASCO GI update should make that a straightforward choice.
👍️0
Deano361 Deano361 3 years ago
yep, something big happening here.
👍️0
crudeoil24 crudeoil24 3 years ago
4.08 > hod.
👍️0
masterofdisaster masterofdisaster 3 years ago
I think I am going to double my position on Monday
👍️0
Deano361 Deano361 3 years ago
Yeah that was super strong after share offer . I think Beigene (sp?) may know this is real and we are a $10 acquisition target next year
👍️0
masterofdisaster masterofdisaster 3 years ago
The daily build up of short exempts on this momentum is driving the move. The cancer treatment results started the move. We shook off the share dump like it was nothing
👍️0
Deano361 Deano361 3 years ago
Yes unbelievable dude . Cancer tests must be solid behind the scenes too
👍️0
masterofdisaster masterofdisaster 3 years ago
I got to tell you we are holding better then I thought. This may squeeze soon
👍️0
Deano361 Deano361 3 years ago
yes, oddly. watch for a pull back.
👍️0
masterofdisaster masterofdisaster 3 years ago
Premarket looks good
👍️0
Deano361 Deano361 3 years ago
yeah it's going to linger for a month now. But once Beigeine exercises their old warrants it's a good sign.
👍️0
masterofdisaster masterofdisaster 3 years ago
Share options were executed for $2.77 up to 15% of OS. DILUTION!!!! See what happens. This timing couldn't be any worse.
👍️0

Your Recent History

NASDAQ
LPTX
Leap Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads